Protein expression is a process in which proteins are synthesized, modified, regulated, and controlled in living organisms according to the host cell. Protein expression in the context of protein research can now also refer to the application of lab procedures necessary for protein production. The main product types for protein expression are reagents, competent cells, expression vectors, services, and instruments. A reagent is a substance or compound that is added to a system in order to produce a chemical reaction or to determine whether or not a reaction occurred. The various forms of protein expression include yeast expression, mammalian expression, algae expression, insect expression, bacterial expression, and cell-free expression that are used for therapeutic, industrial, and research applications. The different end users involve pharmaceutical and biotechnology companies, academic research, and contract research organizations. The protein expression market research report is one of a series of new reports from The Business Research Company that provides protein expression market statistics, including protein expression industry global market size, regional shares, competitors with a protein expression market share, detailed protein expression market segments, market trends and opportunities, and any further data you may need to thrive in the protein expression industry. This protein expression market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global protein expression market will grow from $2.87 billion in 2022 to $3.19 billion in 2023 at a compound annual growth rate (CAGR) of 11.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global protein expression market is expected to grow to $4.96 billion in 2027 at a CAGR of 11.6%. An increase in demand for biologics to counter various genetic disorders and chronic diseases is one the major factors driving the research and sales of protein expression market. Biologics is a medicine produced from living organisms or contains components of living organisms such as protein, tissue, genes, allergens, cells, blood components, blood, and vaccines. The increasing use of biologics (therapeutic protein and others) to cure chronic diseases such as cancer, cardiovascular conditions and genetic disorders, is increasing the demand for protein expression devices and equipment. According to the World Health Organization, chronic disease prevalence rose by 57% globally, in the year 2020. Hence the rising demand for biologics is driving the protein expression market. For instance, according to an article published by Chemistry World, analysts stated that the biologics market hold a market share of more than a quarter of the entire pharmaceutical market in 2020. The global biologics market is expected to grow at 14.7% during 2021-2023. Government regulations related to protein therapeutics and the production of biologics may hinder the protein expression market growth. Government regulations on biologics to undergo rigorous preclinical and clinical trials prior to regulatory approval, and time-consuming process for approval of biologics with regards to health and the safety of any individual are restraining the market growth. Marketing and distribution of biologics including insulin, hormones, therapeutic antibodies, and vaccines depends upon the successful completion of clinical trials, which is a long, expensive, and uncertain process. According to FDA, for an approval of new biologic, Under the regulations (21 CFR 314.81(b)(2)(vii) and 601.70, a clinical trial approval usually takes 10- 12 months where firms are required to submit a report annually on the status of clinical safety, clinical efficiency, clinical pharmacology, and nonclinical toxicology study. Companies in the industry are increasingly adopting Microfluidics technology to enhance protein expression tests in order to reduce the time, cost, labor, and increase in the accuracy and performance. The microfluidics technology effectively analyzes biological samples than the traditional (macroscale) instruments. Microfluidics technology is used to measure the expression of proteins on cells and optimizes the output to generate results regarding protein expression. Therapeutics-on-a-chip (TOC) uses microfluidic platform and is able to synthesize proteins in a point-of-care setting to reduce cost associated with storage and transportation of therapeutic proteins. For instance, companies such as MissionBio, NanoCellect Biomedical, RainDance Technologies and Sphere fluidics have implemented this technology in protein expression test. The Protein Expression market in the U.S. is governed by the Food and Drug Administration (FDA) which lays down a series of guidelines for the manufacturers and retailers of this industry. Within FDA, Centre for Drug Evaluation and research (CDER) regulates biological products under FDA 101 which includes gene therapy products and vaccines. These regulations ensure the quality, safety, and efficacy of biological therapeutics products, and speed up innovations that make these products safer, and effective. The US FDA announced a fast-track initiative to review its drugs and biologics policy to speed the availability of therapies to patients with serious conditions, orphan drugs for rare disease, while preserving the safety and efficacy standards. FDA also removed a rule (Section 610.21 of the FDA code) that specified minimal potency limits for certain antibodies and antigens. The European Medicines Agency has also introduced policies that include a provision to waive the scientific advice fee, which encourages more academic groups and small companies to propose candidates for biologics. Major players in the protein expression market are Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher Scientific Inc., New England Biolabs, Promega Corporation, Qiagen, Takara Bio, Merck KGaA, Genscript Biotech Corporation, Life Technologies Corporation, Sigma-Aldrich Corporation, Lucigen Corporation, Synthetic Genomics Inc., Becton, Dickinson & Company, Lonza Group Ltd., Accelagen Inc., Geneva Biotech, Viva Biotech, Becton, Dickinson & Company, Sengenics, ARTES Biotechnology GmbH, Addgene Inc., Profacgen, ProteoGenix, Peak Proteins Ltd., Domainex Ltd., Jena Bioscience GmbH, EMD Millipore, and Oxford Expression Technologies Ltd. North America was the largest region in the protein expression market in 2022. Western Europe was the second largest region in the global protein expression market. The regions covered in the global protein expression market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the protein expression market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The protein expression market includes revenue earned by instruments, expression kits, and systems. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global protein expression market is segmented - 1) By Protein Expression: Yeast Expression, Mammalian Expression, Algae Expression, Insect Expression, Bacterial Expression, Cell-free Expression 2) By End Use: Pharmaceutical And Biotechnological Companies, Academic Research, Contract Research Organizations 3) By Product: Reagents, Competent Cells, Expression vectors, Services, Instruments 4) By Application: Therapeutic, Industrial, Research

Therapeutic proteins refer to pharmaceuticals that are genetically modified versions of human proteins that are found naturally. These powerful, quick-acting medications were developed in a lab for pharmaceutical usage. Therapeutic proteins have altered how diseases are treated since they are very effective in vivo. The main types of products in therapeutic proteins are insulin, fusion proteins, erythropoietin, interferon, human growth hormone, and follicle-stimulating hormone. Insulin is a peptide hormone produced by beta cells in the pancreatic cells that serves as the individual's primary anabolic hormone. It affects fat, carbohydrate, and protein metabolism by boosting glucose uptake from the blood into the fat, liver, and skeletal muscle cells. The different functions include enzymatic and regulatory activity, special targeting activity, vaccines, and protein diagnostics and are used in various applications such as metabolic disorders, immunologic disorders, haematological disorders, cancer, hormonal disorders, genetic disorders, and others. The therapeutic proteins market research report is one of a series of new reports from The Business Research Company that provides therapeutic proteins market statistics, including industry global market size, regional shares, competitors with a therapeutic proteins market share, detailed therapeutic proteins market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic proteins industry. This therapeutic proteins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global therapeutic proteins market grew from $112.17 billion in 2022 to $125.74 billion in 2023 at a compound annual growth rate (CAGR) of 12.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The therapeutic proteins market is expected to grow from $200.43 billion in 2027 at a CAGR of 12.4%. The therapeutic proteins market is being driven by technological advancements in protein-based drug development. Therapeutic proteins cannot be synthesised chemically, they need to be produced by genetic engineering and recombinant DNA technology in living cells or organisms. Protein-engineering platform technologies such as glycoengineering, pegylation, Fc-fusion, albumin fusion, and albumin drug conjugation help to increase the production yield, product purity, circulating half-life, targeting, and functionality of therapeutic protein drugs. Belimumab, ipilimumab, taliglucerase alfa, albiglutide, and recombinant human coagulation factor IX are some therapeutic protein drugs developed using protein engineering technologies and approved by the FDA in the past five years. Increasing the number of biosimilar drugs on the global market will slow the growth of the therapeutic protein market. The patent expiration of therapeutic proteins such as monoclonal antibodies allows biosimilars to enter the market.For instance, in October 2022, Amneal Pharmaceuticals, Inc., a US-based generics and specialty pharmaceutical company, launched ALYMSYS® (bevacizumab-maly) in the United States. These cost-effective treatments, similar to the original biologics, decline the revenue and sales of therapeutic proteins. Monoclonal antibody drug approvals are increasing in the protein therapeutic segment. Chronic diseases such as cancer and immunological disorders are well treated with monoclonal antibodies. Monoclonal antibodies are a dominant and well-established product class in the protein therapeutic segment, with more safety and immunogenicity than antibodies. By overcoming the problems associated with previous antibody drugs, cell-based expression systems, such as the Chinese hamster ovary (CHO) mammalian cell expression system, have increased the productivity of monoclonal antibodies.In the last five years, the FDA has approved 213 drugs, among which 44 are monoclonal antibodies. For instance, twelve monoclonal antibodies were approved by FDA for the treatment of cancer and immunological disorders. In the United States, therapeutic protein drug manufacturers file a biologics application (BLA) with the FDA for product approval. The drug that is approved through BLA must be proven to be safe, pure, and potent.FDA consolidated review of most therapeutic proteins in the Center for Drug Evaluation and Research (CDER). In European Union, biologics are regulated by Committee for Medicinal Products for Human Use (CHMP) for marketing authorization. Eli Lilly and Company, a US-based pharmaceutical company, paid $1 billion for Protomer Technologies Inc. in July 2021.Lilly is delighted to add protomer’s breakthrough technology to its diabetes pipeline through this acquisition, since the company’s glucose-sensing insulin program, which is based on its proprietary molecular engineering of protein sensors (MEPS) platform, is exhibiting great potential. Protomer Technologies Inc. is a US-based company that specialises in next-generation protein therapies that can detect molecular activators in the body and are currently being developed. Major players in the therapeutic proteins market are Abbott Laboratories, Amgen Inc., Baxter International Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Pfizer Inc., Johnson & Johnson, and Merck & Co. Inc., Novo Nordisk A/S, and Sanofi. North America was the largest region in the therapeutic proteins market in 2022. The regions covered in the global therapeutic proteins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the therapeutic proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The therapeutic proteins market consists of sales of antibody-based drugs, FC fusion proteins, and anticoagulants. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global therapeutic protein market is segmented - 1) By Product Type: Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone 2) By Application: Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, Other Applications 3) By Function: Enzymatic and Regulatory Activity, Special Targeting Activity, Vaccines, Protein Diagnostics

Haematology analyzers provide complete blood count (CBC) with a three-part differential white blood cell (WBC) count and can detect small cell populations to diagnose rare blood conditions, measure cell morphology. The main products in haematology analyzers and reagents are haematology analyzers, hemostasis analyzers, plasma protein analyzers, haemoglobin analyzers, erythrocyte sedimentation rate analyzers, coagulation analyser, flow cytometers, slide stainers, differential counters, and haematology stains. The hematology analysers are devices that measure the concentration of haemoglobin in a blood sample. The various applications include anemias, blood cancers, hemorrhagic conditions, infection-related conditions, immune system-related conditions, and others that are used by end-users such as specialised research institutes, hospitals, specialised diagnostic centres, and others. The haematology analyzers and reagents market research report is one of a series of new reports from The Business Research Company that provides haematology analyzers and reagents market statistics, including haematology analyzers and reagents industry global market size, regional shares, competitors with a haematology analyzers and reagents market share, detailed haematology analyzers and reagents market segments, market trends and opportunities, and any further data you may need to thrive in the haematology analyzers and reagents industry. This haematology analyzers and reagents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global hematology analyzers and reagents market grew from $4.14 billion in 2022 to $4.56 billion in 2023 at a compound annual growth rate (CAGR) of 10.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hematology analyzers and reagents market is expected to grow from $5.67 billion in 2027 at a CAGR of 5.6%. The rising number of blood donations globally is driving the hematology analyzers and reagents market as hematology analyzers are used to test and screen blood in blood banks. Blood collected from donors through blood donation camps or bloodmobiles is sent to blood banks where hematology analyzers are used to screen and test the blood. These screening tests determine the blood type, analyze the blood plasma and detect infectious diseases. Blood banks are witnessing a huge outflow of blood to hospitals and other end-users and an inflow of blood from blood donations daily. According to the WHO, there was an increase of 7.8 million blood donations from voluntary unpaid donors. As the number of people donating blood increases, the demand for hematology analyzers and reagents increases, thereby driving the market growth. Recalls of defective hematology analyzers are acting as a restraint on the hematology analyzers and reagents market. A product recall is done by the manufacturer or developer of the product as a precautionary measure when safety issues or defects are discovered that can endanger the consumer. A faulty hematology analyzer may provide wrong results and may lead to misdiagnosis, affecting consumer confidence in the analyzers. Regulatory authorities caution healthcare professionals to be aware of the potential for inaccurate diagnostic results with these analyzers and to take appropriate actions including the use of alternative diagnostic testing or confirming analyzer results with manual scanning or estimate of cell counts. For instance, Beckman Coulter Life Sciences recalled its DxH800 and DxH600, and DxH 900 hematology analyzers due to the risk of inaccurate results. Such kind product recalls not only pose a serious safety risk to the public but can also cause significant financial and reputational damage to the companies concerned. Hematology analyzers manufacturers are increasingly investing in the research and development of analyzers with microfluidics technology that use low volumes of samples and reagents. Microfluidics deal with the flow of liquids inside channels as small as a few micrometers. Low reagent consumption by hematology analyzers with microfluidics technology helps reduce operating costs significantly. For instance, the HA5 hematology system from BioSystems is based on microfluidics technology and uses approximately 75% fewer reagents compared to normal hematology analyzers. Also, the respons®3H and respons®5H hematology systems by DiaSys use microfluidics technology and consume 70% fewer reagents. In May 2021, Soulbrain, a South Korean chemicals company, acquired PixCell Medical for an undisclosed amount. The acquisition would support Soulbrain’s growth strategy in the fields of diagnostics and point-of-care testing. PixCell is an Israeli maker of blood test analyzers. Major players in the haematology analyzers market are Abbott, Bio-Rad Laboratories, Horiba, Siemens, Sysmex, BioSystems, Boule, Danaher, Diatron, and Drew Scientific. North America was the largest region in the haematology analyzers market in 2022. Western Europe was the second largest region in the global haematology analyzers market report. The regions covered in the global haematology analyzers and reagents report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the haematology analyzers market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The haematology analyzers market consists of sales electrolyte analyzer, hemocoagulometer, enzyme standard instrument, blood gas analyzer and immunoturbidimeter. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global haematology analyzers and reagents market is segmented - 1) By Product: Hematology Analysers, Hemostasis Analysers, Plasma Protein Analysers, Hemoglobin Analysers, Erythrocyte Sedimentation Rate Analyser, Coagulation Analyser, Flow Cytometers, Slide Stainers, Differential Counters, Hematology Stains 2) By Applications: Anemias, Blood Cancers, Hemorrhagic Conditions, Infection Related Conditions, Immune System Related Conditions, Other Applications 3) By End User: Specialized Research Institutes, Hospitals, Specialized Diagnostic Centers, Other End Users

Biostimulants are substances or microorganisms that enhance plant growth when applied in small amounts by increasing the nutrient absorbency rate of plants without any adverse effect on the plants. It improves plant tolerance to biotic stress while also increasing crop productivity. The chemical origin of biostimulants includes natural and biosynthetic biostimulants. Biosynthetic biostimulants are defined as the microorganisms that are applied to plants for the purpose of enhancing their abiotic stress tolerance, nutrition efficiency, and quality traits. The main active ingredients of biostimulants are humic acid, fulvic acid, amino acids, protein hydrolysates, seaweed extracts, and other active ingredients. The various applications of biostimulants are foliar, soil, seed, and other applications. The biostimulants market research report is one of a series of new reports from The Business Research Company that provides biostimulant market statistics, including biostimulant industry global market size, regional shares, competitors with a biostimulant market share, detailed biostimulant market segments, market trends and opportunities, and any further data you may need to thrive in the biostimulant industry. This biostimulants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global biostimulants market size will grow from $2.79 billion in 2022 to $3.01 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global biostimulants market size is expected to grow from $4.09 billion in 2027 at a CAGR of 8.0%. The growth of sustainable agriculture is expected to drive the growth of the biostimulant market. There is an increased focus on sustainable agriculture due to deteriorating factors such as soil degradation, water scarcity, climate change, and also the burden of producing high crop yields to meet the demand. In sustainable agriculture, the use of artificial products like fertilizers and pesticides is prohibited since it degrades soil and harms the environment. Biostimulants, on the other hand, increase the simulation power of the plants to absorb nutrients and help in handling biotic stress. For instance, the United Nations' sustainable development goals for 2030 have a special focus on sustainable agriculture. The use of biostimulants to grow crops free of pesticides and fertilizers also helps in growing crops under unusual conditions. The use of biostimulants helps grow various crops under stress conditions, supporting sustainable agriculture and thereby driving the biostimulant market. Uncertainty about the legal framework for biostimulants is expected to hinder the biostimulant market. Documentation on the labelling and efficacy of biostimulants is not available, and definitions of biostimulants are different worldwide. For instance, the US and Europe lack a specific biostimulant regulatory framework. The Europe has published the new European Fertilizer Regulation (EC) No. 2019/1009 that includes a biostimulants definition and a regulatory path for registrations of such products across the EU states. Moreover, the EU regulation is expected to become effective in 2022 and new standards for processes and methods are expected to be developed in the next few years. Thus, an uncertain legal framework hinders the biostimulant market. Companies in the biostimulant market are coming up with innovative products to meet the demand and requirements of the customers and have an edge over their competitors. Mostly, start-ups are entering the market with new products. For example, in June 2022, a Spanish provider of biostimulation and sustainable crop nutrition introduced Biimore, an innovative biostimulant globally. It is made from specific and sustainable plant fermentation process from a combination of L-a amino acids, vitamins, sugars and traces of other natural compounds that are not found in any other biostimulant on the market. It improves yield and harvest quality parameters at ultra-low doses. In addition, in September 2022, Evonik Industries, a German specialty chemicals company commenced the development of an innovative biostimulant that reduces fertilizer use by half and keeps 93% of the yields. This is expected to be launched during 2025-2027. In November 2022, J.M. Huber Corporation, a US-based chemical manufacturing company acquired Biolchim Group for an undisclosed sum. The acquisition reinforces Huber's vision of becoming the world's leading provider of sustainable, high-performance agricultural products. Biolchim Group is an Italian manufacturer of a complete range of specialty plant nutrition and biostimulants. Major players in the biostimulants market are BASF, Bayer CropScience, Novozymes A/S, Koppert Biological Systems, Verdesian Life Sciences, Lallemand Plant Care, Valagro, Syngenta, West Coast Marine Bio-Processing Corp., and Italpollina S.p.A. Asia-Pacific was the largest region in the biostimulants market in 2022. North America was the second-largest region in the global biostimulants market. The regions covered in the global biostimulants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the biostimulants market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The biostimulants market consists of the sales of plant extract, inorganic compound, chitosan and other biopolymer, and beneficial microbe biostimulants. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global biostimulants market is segmented - 1) By Chemical Origin: Natural, Biosynthetic Biostimulants 2) By Active Ingredient: Humic Acid, Fulvic Acid, Amino Acids, Protein Hydrolysates, Seaweed Extracts, Other Active Ingredients 3) By Application: Foliar, Soil, Seed, Other Applications

Biosimilars are medications made from living things, though they can be made in a variety of ways and with slightly different materials. Due to the intricacy and high cost of their creation, as well as their molecular size and structure, biosimilars are fundamentally distinct from generic drugs. The main types of biosimilars are human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, and others. Erythropoietin is a hormone produced by the kidneys to stimulate the production and maintenance of vital red blood cells. The various products include recombinant non-glycosylated proteins and recombinant glycosylated proteins that are used for the treatment of oncology, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and others. The biosimilars market research report is one of a series of new reports from The Business Research Company that provides biosimilars market statistics, including biosimilars industry global market size, regional shares, competitors with a biosimilars market share, detailed biosimilars market segments, market trends, and opportunities, and any further data you may need to thrive in the biosimilars industry. This biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global biosimilars market grew from $19.1 billion in 2022 to $23.28 billion in 2023 at a compound annual growth rate (CAGR) of 21.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The biosimilars market is expected to grow from $47.82 billion in 2027 at a CAGR of 19.7%. The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to be a major driver of the biosimilars market. Long working hours, limited physical activity, and unhealthy eating and drinking habits contribute to the prevalence of chronic diseases and biosimilars are increasingly used to treat these chronic diseases. Biosimilars activate the immune system response against cancer cells thus helping the immune system to eliminate the cancer cells from the body. According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biosimilars, thus driving the biosimilars market. The lack of awareness about biosimilars among primary care physicians (PCPs) and specialists limits the growth of the biosimilars market. Biosimilars are manufactured from cell lines and offer the same effectiveness as biologics. However, a lack of familiarity with biosimilars reduces the likelihood of prescribing the drugs to patients which affects the demand for new biosimilars in the market. For instance, according to the PwC’s Health Research Institute, out of 442 clinicians surveyed 55% of clinicians were unfamiliar with biosimilars and 35% were reluctant to prescribe them due to concerns including the safety of the follow-on biologic. Thus, the lack of awareness about biosimilars among primary care physicians (PCPs) and specialists restricts the growth of the biosimilars market. Production of new insulin biosimilars is trending in the biosimilars market. The key players operating in the biosimilars market are investing in creating a biosimilar of insulin. This is also promoting competition among various biosimilar manufacturers. For instance, in August 2020, Biocon Biologics India Ltd., an India-based fully integrated global biosimilars organization, in partnership with Mylan, a US-based biosimilar company, has launched Semglee, insulin glargine injection in the U.S. to aid in lowering blood sugar levels in adults with type 2 diabetes and children with type 1 diabetes. Major players in the biosimilars market are Pfizer, Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Boehringer Ingelheim, Elli Lilly and Company, Mylan N.V., Sanofi, STADA Arzneimittel, Sandoz International, Samsung Bioepis, Teva Pharmaceuticals, Apotex, AMEGA Biotech S.A., Bioton S.A., Innovent Biologics International, Allergan PLC., BioXpress Therapeutics, 3SBio, Intas Biopharmaceuticals, Lupin Merck, Novartis, Ratiopharm, Wockhardt, Zydus Cadila, Allergan PLC., Hospira International., Actavis International., Johnson & Johnson and Roche. North America was the largest region in the global biosimilars market in 2022. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the global biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The biosimilars market consists of sales of binocrit, epoetin alfa hexal, and abseamed. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global biosimilars market is segmented - 1) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins 2) By Types: Human Growth Hormone, Erythropoietin, Monoclonal antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor, Other Types 3) By Application: Oncology, Chronic and Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Proteomics is the study of the structure and functions of proteins that are used in drug discovery, diagnosis, and treatment of diseases. Proteomics is used to evaluate the protein production rate, the involvement of proteins in metabolic pathways, and the modifications of proteins. The main types of proteomics are protein microarrays, spectroscopy, X-ray crystallography, chromatography, electrophoresis, surface plasmon resonance, and protein fractionation. The various components used are reagents, instruments, and software that are used for proteomic analytical services and instrument services. The proteomics market research report is one of a series of new reports from The Business Research Company that provides proteomics market statistics, including proteomics industry global market size, regional shares, competitors with a proteomics market share, detailed proteomics market segments, market trends, and opportunities, and any further data you may need to thrive in the proteomics industry. This proteomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global proteomics market grew from $26.98 billion in 2022 to $31.28 billion in 2023 at a compound annual growth rate (CAGR) of 15.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The proteomics market is expected to grow from $50.79 billion in 2027 at a CAGR of 12.9%. Rising government funds for research on proteomics drives the growth of the proteomics market. Government funds help researchers in drug discovery, diagnosis, and treatment of diseases. For instance, in 2020, the IRB Barcelona's Mass Spectrometry and Proteomics Core Facility, which is led by a research team with extensive expertise in the field, has received funding from the Catalan government through the European Regional Development Fund (ERDF) to purchase next-generation protein analysis equipment in collaboration with the Josep Carreras Leukemia Research Institute (IJC), the Sant Joan de Déu Research Institute (SJD), the Vall d'Hebron Institute of Oncology (VHIO), and the (UB). Therefore, rising government funds positively impacts the proteomics market. The high cost of instruments is expected to limit the growth of the proteomics market. The broad implementation of new technologies expands the use of proteomics research from the discovery of new drugs, vaccines, and diagnostic targets, and due to its high-cost process, developments in different instruments have resulted in high prices compared to the traditional ones. For instance, the price of mass spectrometers can range from $20,000 to $300,000, which will be extremely expensive for small-scale pharmaceutical companies and academic institutions. Therefore, the high prices associated with proteomics instruments make it difficult for developing countries to enter the proteomics sector, affecting the market’s growth. Companies are launching new products in order to increase their revenue and also gain a competitive edge over their rivals. For instance, in June 2021, Bruker Corporation, a USA-based scientific instruments manufacturing company, announced the availability of two new trapped ion mobility spectrometry time-of-flight (timsTOF) instruments at its 4D-Proteomics eXceed Symposium. The devices, which are based on ion mobility separation and mass spectrometry, will provide additional advances in proteomics, epiproteomics/PTM characterisation, and deep multiomic biomarker discovery. In January 2020, Abcam, a UK-based company specialized in manufacturing research-grade antibodies, acquired Expedeon's proteomics and immunology business for an undisclosed amount. The acquisition is expected to help Abcam enhance its protein conjugation technology and create new products to support research and diagnostic development. Expedeon Ltd. is a UK-based company that specializes in the development of next-generation tools for biological research, diagnostics, and drug discovery. Major players in the proteomics market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Danaher Corporation, Merck KGaA, Waters Corporation, Perkinelmer Inc., Bio-Rad Laboratories Inc., Bruker Corporation, GE Healthcare, Caprion Biosciences, Luminex Corporation, LI-COR Inc., Becton Dickinson and Company, Siemens Ltd., Genzyme Corporation, Creative Proteomics, and Promega Corporation. North America was the largest region in the proteomics market in 2022. Western Europe was the second largest region in the global proteomics market. The regions covered in the global proteomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the proteomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The proteomics market consists of sales of proteins that are used for drug discovery, clinical diagnosis, molecular medicine and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global proteomics market is segmented - 1) By Component: Reagents, Instruments 2) By Instrument: Protein Microarrays, Spectroscopy, X-ray Crystallography, Chromatography, Electrophoresis, Surface Plasmon Resonance, Protein Fractionation 3) By Service and Software: Core Proteomics Services, Bioinformatics Software & Services

Protein inhibitors refer to compounds that interfere with the steps directly involved in the production of new proteins in cells. Protein inhibitors operate at the ribosome level, benefiting from the significant variations between prokaryotic and eukaryotic ribosome architectures. The main product types of protein inhibitors are protein kinase inhibitors, monoclonal antibodies, and others. Monoclonal antibodies are laboratory-created molecules designed to act as substitute antibodies, restoring, enhancing, modifying, or mimicking the immune system's attack on unwanted cells, such as cancer cells. The protein inhibitors are used in the treatment of oncology, inflammatory diseases, and others, and are distributed by hospital pharmacies, independent pharmacies, and online pharmacies. The protein inhibitors market research report is one of a series of new reports from The Business Research Company that provides protein inhibitors market statistics, including protein inhibitors industry global market size, regional shares, competitors with a protein inhibitors market share, detailed protein inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the protein inhibitors industry. This protein inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global protein inhibitors market grew from $68.17 billion in 2022 to $74.3 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The protein inhibitors market is expected to grow from $105.43 billion in 2027 at a CAGR of 9.1%. The increasing prevalence of chronic diseases is predicted to contribute to the growth of the protein inhibitors market over the forecast period. Chronic diseases such as cancer, cardiovascular diseases, and autoimmune diseases are becoming more prevalent. For instance, in May 2022, according to the World Health Organization, chronic diseases are expected to become the seventh leading cause of death globally by the end of 2030.In the USA, the number reached 157 million in 2020, with 87 million people having multiple conditions. Protein inhibitors are used for the treatment of these diseases attributing to fewer adverse effects and higher efficacy. Therefore, an increasing number of people with chronic diseases are anticipated to propel the demand for protein inhibitors market. The high cost of protein inhibitors used for cancer is anticipated to limit the growth of the protein inhibitors market shortly. Monoclonal antibodies are a type of protein made in the laboratory to bind substances in the body including cancer cells and are used to treat various types of cancer. Monoclonal antibody therapies are considered to be costlier when used for cancer. For instance, according to the National Center for Biotechnology Information, the average price of monoclonal antibodies was $96,731 for 34 monoclonal antibody indication combinations. Oncology and hematology monoclonal antibodies represented 40% of approved monoclonal antibody indication combinations, yet accounted for more than 85% of those priced at $100,000 or higher. The price of oncology or hematology monoclonal antibodies was $149,622 higher than those used in metabolic or cardiovascular disorders, $106,830 higher than in ophthalmology, $128,856 higher than in infectious diseases or allergies, and $98,981 higher than in immunology. Thus, the high cost of protein inhibitors including monoclonal antibodies for the treatment of cancer is expected to hinder the market’s growth. Companies in the protein inhibitors market are increasingly investing in various strategic initiatives such as partnerships and collaborations to develop new drugs to meet the market demand. Strategic collaborations and partnership agreements help companies to expand their existing product portfolio and geographical presence. For instance, in February 2020, Catalent, Inc., a USA-based provider of delivery technologies, drug manufacturing, gene therapies, biologics, and consumer healthcare products announced a partnership agreement with Zumutor Biologics Inc., an immune-oncology company based in the USA to manufacture ZM008, a monoclonal antibody targeting solid tumors. Moreover, in February 2021, Eli Lilly and Company, a USA-based pharmaceutical company, and Rigel Pharmaceuticals, Inc., a USA-based biotechnology company, announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications, including autoimmune and inflammatory diseases. In June 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, acquired ReViral for $525 million. The acquisition strengthens Pfizer's commitment to creating both medications and vaccines to help fight the respiratory syncytial virus while also expanding its anti-infective portfolio (RSV). ReViral is a UK-based clinical-stage biopharmaceutical company pioneering in the discovery and development of innovative antiviral drugs for disorders brought on by the respiratory syncytial virus. Major players in the protein inhibitors market are Bayer AG, Astra Zeneca, Roche, Teva, Apotex, Novartis, GlaxoSmithKline, Pfizer, Boehringer Ingelheim, and F. Hoffmann-La Roche. North America was the largest region in the protein inhibitors market in 2022. The regions covered in the global protein inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the global protein inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The protein inhibitors market consists of sales of erythromycin, tetracycline, chloramphenicol, and aminoglycosides. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global protein inhibitors market is segmented - 1)By Product: Protein Kinase Inhibitors, Monoclonal Antibody, Other Products 2)By Application: Oncology, Inflamatory Diseases, Other Applications 3)By Distribution Channel: Hospital Pharmacies, Independent Pharmacies, Online Pharmacies

Textured pea protein is a protein supplement that is extracted from peas to create high-protein, plant-based meat substitutes. It is a naturally gluten-free and soy-free product with a pleasant taste and texture, offering it an ideal complement to popular ingredients in a variety of applications. Textured pea protein is non-GMO and has low allergenicity which makes it a great alternative to wheat and soy products. The main types of products in textured pea protein are yellow peas and green peas. Field peas, often known as yellow peas, are a type of pea that is best dried rather than eaten fresh. The peas' skin (seed coat) is a pale yellow color. The peas are a deeper yellow inside, but the color disappears when cooked. It has both organic and conventional nature and has different processing types such as dry processing, wet processing. It is implemented in various verticals such as food processing, animal feed, nutraceuticals, sports nutrition, infant nutrition, cosmetic and personal care, others. The textured pea protein market research report is one of a series of new reports from The Business Research Company that provides textured pea protein market statistics, including textured pea protein industry global market size, regional shares, competitors with a textured pea protein market share, detailed textured pea protein market segments, market trends and opportunities, and any further data you may need to thrive in the textured pea protein industry. This textured pea protein market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global textured pea protein market size grew from $0.53 billion in 2022 to $0.59 billion in 2023 at a compound annual growth rate (CAGR) of 10.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The textured pea protein market size is expected to grow to $0.82 billion in 2027 at a CAGR of 8.8%. The rising consumer interest in plant-based protein is contributing to the growth of the textured pea protein market. In recent years, consumer interest in plant-based diets has increased significantly with vegan, vegetarian, and flexitarian diets becoming quite prevalent. The protein level of textured pea protein components is among the highest on the globe, with a pleasant taste and attractive texture. According to the Good Food Institute published report in 2021, a US-based non-profit organization to promote plant-based and cell-based alternatives to animal products, sales of plant-based foods increased three times more quickly than those of non-plant-based meals as compared to its previous years in the year 2021 in the US. Therefore, the rising consumer interest in plant-based proteins propels the growth of the textured pea protein market. The launch of organic pea protein isolate is an emerging trend in the textured pea protein market. Major companies operating in the textured pea protein sector are focused on introducing organic pea protein to meet the consumer demand for organic protein products. For instance, in June 2021, Roquette Freres, a France-based company operating in plant-based ingredients, announced the launch of NUTRALYS, a range of organic textured proteins from peas and fava beans. NUTRALYS provides 11 levels of textured proteins that provide a wide range of forms and textures with a neutral flavor and clean label, enabling a variety of meals that substitute meat and fish and offer the possibility to develop both tasty and organic plant-based gastronomy. In February 2020, Kerry Group, an Ireland-based food company acquired Pevesa Biotech S.A. for an undisclosed amount. This acquisition aims at strengthening Kerry Group’s position in the hydrolyzed plant protein space for specialized nutrition and expanding the company’s capacity to serve the rapidly growing organic plant protein market. Pevesa Biotech S.A. is a Spain-based company engaged in offering a range of proteins, including organic pea and rice protein and protein hydrolysates. Major players in the textured pea protein market are Roquette, Puris Foods, Burcon Nutrascience Corporation, Nisco ApS, Sotexpro, Exeller N.V., Vestkorn Milling AS, Nutri-Pea Limited, Cosucra Groupe Warcoing SA, Scoular, Axiom Foods Inc., AGT Foods, The Green Labs LLC, DuPont Nutrition & Biosciences, Shandong Jianyuan Group, and Kerry Group plc. North America was the largest region in the textured pea protein market in 2022. Europe was the second-largest market in the textured pea protein market. The regions covered in the textured pea protein report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the textured pea protein market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The textured pea protein market consists of sales of green peas and yellow peas. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global textured pea protein market is segmented - 1) By Product Type: Yellow Peas, Green Peas 2) By Nature: Organic, Conventional 3) By Processing Type: Dry Processing, Wet Processing 4) By End Use: Food Processing, Animal Feed, Nutraceuticals, Sports Nutrition, Infant Nutrition, Cosmetic And Personal Care, Other End-users